BRADY LOWELL J.,Brady Lowell J.,KLUCHER KEVIN M.,Klucher Kevin M.,CHAN CHUNG,Chan Chung,DONG DENNIS L.,Dong Dennis L.,LIU HONG Y.,Liu Hong Y.,SHEPPARD PAUL O.,Sheppard Paul O.,BUKOWSKI THOMAS R.,Bukow
申请号：
SI200432036
公开号：
SI2251353T1
申请日:
2004.08.09
申请国别(地区):
SI
年份:
2013
代理人:
摘要：
FIELD: biotechnology. ^ SUBSTANCE: invention relates to biotechnology, particularly to genetic engineering and it can be used in the biomedical industry to produce active medications of interleukin-29 (IL-29). Mutant forms of IL-29 (SEQ ID NO: 27, 29, 40, 41, 149 and 159) were offered with substitution of the cysteine residue in the position in accordance with position 171 of the aminoacid sequence of a mature protein of a wild type that are characterised by a correct formation of intramolecular disulfide bonds and accordingly they provide production of polypeptides with an antiviral activity as homogeneous medications at expression in the heterologous system. ^ EFFECT: vector structures and the host cells transformed by these structures for the expression of new versions of IL-29 are described. ^ 15 cl, 37 tbl, 45 ex
